Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Low density of sigma-1 receptors in early Alzheimer’s disease.

April 10, 2008

ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity

March 10, 2008

Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008

January 22, 2008

Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

December 28, 2007

Anavex Strengthens Board of Directors

December 17, 2007

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

December 11, 2007

Anavex Advances Drug Candidates for Treatment of Epilepsy

December 6, 2007

Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines.

December 1, 2007

Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia.

November 3, 2007

Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services

November 2, 2007

Modulation of brainstem opiate analgesia in the rat by σ1 receptor: A microinjection study.

September 11, 2007

Annual General Meeting of the Shareholders of Anavex Life Sciences Corp.

June 5, 2007
1
23456789101112131415161718192021222324252627282930
…3132333435…
363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top